We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
- Recent ICPT Stock Price: $13.48
- Yearly Gain for ICPT stock: -6.69%
- Market Cap for ICPT stock: $573.73M
- P/E Ratio for ICPT stock: -6.408
Will ICPT's stock price go up? Is there an accurate ICPT stock forecast available?
TipRanks.com reports that Intercept Pharma currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $24.00. The target pricing ranges from a high ICPT forecast of $49.00 down to a low forecast of $14.00. Intercept Pharma (ICPT)’s last closing stock price was $13.48 which would put the average price target at 78.04% upside.
In addition, TradingView issued a Strong Sell rating for ICPT stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT stock.
Other analysts covering ICPT include:
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $ 35 on 22 hours ago
- Thomas Smith of SVB Securities issued a Hold rating with the price target of $ 17 on 22 hours ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $ 15 on 3 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 49 on 3 days ago
If you are wondering if ICPT is a good stock to buy, here are 3rd party ratings for ICPT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 34% (85 out of 251)
What is the sentiment on the street regarding Intercept Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ICPT stock: Very Bullish
- Blogger Consensus for ICPT stock: Bearish
- Media Buzz for ICPT stock: Low
- Insider Signal for ICPT stock: n/a
- Investor Sentiment for ICPT stock: Negative
- Hedge Fund signal for ICPT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ICPT stock including scouring the social networks like ICPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ICPT stock chart >>
Summary: Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
- Recent RCKT Stock Price: $15.5
- Yearly Gain for RCKT stock: -44.96%
- Market Cap for RCKT stock: $1.05B
- P/E Ratio for RCKT stock: -5.376
Will RCKT's stock price go up? Is there an accurate RCKT stock forecast available?
TipRanks.com reports that Rocket Pharmaceuticals currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $57.71. The target pricing ranges from a high RCKT forecast of $75.00 down to a low forecast of $34.00. Rocket Pharmaceuticals (RCKT)’s last closing stock price was $15.5 which would put the average price target at 272.32% upside.
In addition, TradingView issued a Buy rating for RCKT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RCKT stock.
Other analysts covering RCKT include:
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 65 on 3 days ago
- Joshua Schimmer of Evercore ISI issued a Buy rating with the price target of $ 75 on 3 days ago
- Patrick Dolezal of LifeSci Capital issued a Buy rating with the price target of $ 50 on 3 days ago
If you are wondering if RCKT is a good stock to buy, here are 3rd party ratings for RCKT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 34% (85 out of 251)
What is the sentiment on the street regarding Rocket Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for RCKT stock: Very Bullish
- Blogger Consensus for RCKT stock: Bullish
- Media Buzz for RCKT stock: High
- Insider Signal for RCKT stock: n/a
- Investor Sentiment for RCKT stock: Negative
- Hedge Fund signal for RCKT stock: Positive
The stock market is extremely volatile, and you need to do your own research on RCKT stock including scouring the social networks like RCKT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RCKT stock chart >>
Summary: Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical stage. Axcella Health Inc. is based in Cambridge, Massachusetts.
- Recent AXLA Stock Price: $1.93
- Yearly Gain for AXLA stock: -40.63%
- Market Cap for AXLA stock: $90.02M
- P/E Ratio for AXLA stock: -0.986
Will AXLA's stock price go up? Is there an accurate AXLA stock forecast available?
TipRanks.com reports that Axcella Health currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.50. The target pricing ranges from a high AXLA forecast of $10.00 down to a low forecast of $6.00. Axcella Health (AXLA)’s last closing stock price was $1.93 which would put the average price target at 340.41% upside.
In addition, TradingView issued a Neutral rating for AXLA stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AXLA stock.
Other analysts covering AXLA include:
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of n/a on 3 days ago
- Robert LeBoyer of Noble Financial issued a Buy rating with the price target of $ 9 on 3 days ago
- Liana Moussatos of Wedbush issued a Buy rating with the price target of $ 9 on 3 days ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 6 on 1 month ago
If you are wondering if AXLA is a good stock to buy, here are 3rd party ratings for AXLA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 34% (85 out of 251)
What is the sentiment on the street regarding Axcella Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for AXLA stock: Very Bullish
- Blogger Consensus for AXLA stock: Bullish
- Media Buzz for AXLA stock: Very High
- Insider Signal for AXLA stock: n/a
- Investor Sentiment for AXLA stock: Neutral
- Hedge Fund signal for AXLA stock: Positive
The stock market is extremely volatile, and you need to do your own research on AXLA stock including scouring the social networks like AXLA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AXLA stock chart >>
Summary: Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
- Recent CYTK Stock Price: $51.11
- Yearly Gain for CYTK stock: 33.14%
- Market Cap for CYTK stock: $4.56B
- P/E Ratio for CYTK stock: -18.675
Will CYTK's stock price go up? Is there an accurate CYTK stock forecast available?
TipRanks.com reports that Cytokinetics currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $68.11. The target pricing ranges from a high CYTK forecast of $82.00 down to a low forecast of $60.00. Cytokinetics (CYTK)’s last closing stock price was $51.11 which would put the average price target at 33.26% upside.
In addition, TradingView issued a Buy rating for CYTK stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYTK stock.
Other analysts covering CYTK include:
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 75 on 22 hours ago
- Salim Syed of Mizuho Securities issued a Buy rating with the price target of $ 80 on 3 days ago
- Charles Duncan of Cantor Fitzgerald issued a Buy rating with the price target of $ 69 on 1 month ago
- Justin Kim of Oppenheimer issued a Buy rating with the price target of $ 60 on 1 month ago
If you are wondering if CYTK is a good stock to buy, here are 3rd party ratings for CYTK stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (85 out of 251)
What is the sentiment on the street regarding Cytokinetics? (Current ratings compiled by TipRanks.com)
- News Sentiment for CYTK stock: Very Bullish
- Blogger Consensus for CYTK stock: Bullish
- Media Buzz for CYTK stock: Low
- Insider Signal for CYTK stock: Negative
- Investor Sentiment for CYTK stock: Neutral
- Hedge Fund signal for CYTK stock: Negative
The stock market is extremely volatile, and you need to do your own research on CYTK stock including scouring the social networks like CYTK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CYTK stock chart >>
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
- Recent AXSM Stock Price: $45.33
- Yearly Gain for AXSM stock: 36.74%
- Market Cap for AXSM stock: $1.80B
- P/E Ratio for AXSM stock: -11.382
Will AXSM's stock price go up? Is there an accurate AXSM stock forecast available?
TipRanks.com reports that Axsome Therapeutics currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $96.00. The target pricing ranges from a high AXSM forecast of $210.00 down to a low forecast of $54.00. Axsome Therapeutics (AXSM)’s last closing stock price was $45.33 which would put the average price target at 111.78% upside.
In addition, TradingView issued a Sell rating for AXSM stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AXSM stock.
Other analysts covering AXSM include:
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 90 on 3 days ago
- Vikram Purohit of Morgan Stanley issued a Hold rating with the price target of $ 71 on 3 days ago
- Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $ 76 on 4 days ago
- Marc Goodman of SVB Securities issued a Buy rating with the price target of $ 75 on 1 month ago
If you are wondering if AXSM is a good stock to buy, here are 3rd party ratings for AXSM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 34% (85 out of 251)
What is the sentiment on the street regarding Axsome Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AXSM stock: Very Bullish
- Blogger Consensus for AXSM stock: Bullish
- Media Buzz for AXSM stock: Low
- Insider Signal for AXSM stock: n/a
- Investor Sentiment for AXSM stock: Negative
- Hedge Fund signal for AXSM stock: Negative
The stock market is extremely volatile, and you need to do your own research on AXSM stock including scouring the social networks like AXSM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AXSM stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================